to a deterministic sigmoidal equation that more realistically represents observed data and used likelihood maximized over several different read depths to improve accuracy over a wide range of values of viral load. Given the proportion of the genome covered at varying depths for a single sample as input data, our model estimated the Ct of that sample as the value that produces the maximum likelihood of generating the observed genome coverage data.

**Results.** The model fit on 87 SARS-CoV-2 NGS assay training samples produced a good fit to the 22 validation samples, with a coefficient of correlation (r2) of ~0.8. The accuracy of the model was high (mean absolute % error of ~10%, meaning our model is able to predict the Ct value of each sample within a margin of ±10% on average). Because of the nature of the commonly used ARTIC protocol, we found that all quantitive signals in this data were lost during PCR amplification and the model is not applicable for quantification of samples captured this way. The ability to model quantification is a major advantage of the SARS-CoV-2 NGS assay protocol.

The likelihood-based model to estimate SARS-CoV-2 viral titer

---

**Disclosure.** Natalie J Dailey Garnes, MD, MPH, AlloVir (Other Financial or Material Support, collaborator on research protocol)

---

357. A Comparison of Chest CT Findings in Cancer and Non-Cancer Patients with COVID-19

Alexandre Malek, MD1; Hiba Dagher, MD2; Ray Y. Hachem, MD2; Yiang Jiang, MS2; Anne-Marie Chaffari, MD1; Issam I. Raad, MD1; UT MD Anderson Cancer Center, Houston, TX;2 MD Anderson Cancer Center, Houston, TX;3 The University of Texas MD Anderson Cancer Center, Houston, TX

**Session:** P-15. COVID-19 Diagnostics

**Background.** The purpose of this study was to compare chest computed tomography (CT) scan findings in cancer versus non-cancer patients with COVID-19 infection. We sought to assess the correlation between radiologic patterns of COVID-19 pneumonia, clinical course, and outcomes.

**Results.** We performed a retrospective study of COVID-19 positive cancer and non-cancer pts who had chest CT scans at the time of diagnosis, at our hospital and 16 other centers in Asia, Australia, Europe, North America and South America, over the time period March, 2020 and November, 2020. Patients’ age, underlying diseases, symptoms, laboratory studies, and radiologic findings consisting of bilateral ground glass opacities (GGOs), multifocal organizing pneumonia (MOP) were collected in association with clinical outcomes.

**Conclusion.** We identified 426 pts with cancer and 622 non-cancer pts. Thereafter, cancer pts were analyzed into 3 distinct groups and similar to non-cancer pts: GGOs group (n=224, 54%), GGOs+MOP group (n=61, 14.6%), and a third group of neither GGOs or MOP (n=131, 31.4%) in cancer pts, and in non-cancer pts: GGOs group (n=387, 62.8%), GGOs +MOP group (n=100, 16.2%), and a third group of neither GGOs or MOP (n=129, 21.6%). The median patients’ age was 54 in non-cancer pts vs 62 in cancer pts (p < 0.001) and there were more males in the non-cancer group 57% vs 47% (p<0.001). Cough was more prevalent in non-cancer pts, 71% vs 59% (p<0.001) and similar to fever (73% vs 57%, p<0.001). Neutropenia < 0.5 k/µL and lymphocytopenia < 1 k/µL were more prevalent in cancer pts (p<0.001). In cancer pts, there was no statistically significant difference between the 3 groups (hospital admission, mechanical ventilation, readmission within 30 days, and mortality), except pts who required non-invasive (NI) ventilation were more frequent in the GGOs group, 55% (p=0.005). In non-cancer pts with GGOs +MOP have higher hospital admission, ICU transfer, NI- and mechanical ventilation compared to the 2 other groups (p<0.001). While readmission to hospital or mortality rate within 30 days were similar between the 3 groups.

**Conclusion.** We studied retrospective case-control study of COVID-19 positive cancer and non-cancer pts that had chest CT scans at the time of diagnosis, and we were associated with more worrisome COVID-19-related clinical outcomes.

**Disclosures.** All Authors: No reported disclosures

---

358. Early Cardiac Marker of Mortality in COVID-19

Douglas Salgueiro, MD; Juliana Ferri-Guerra, MD; Angel Porras, MD; Marissa Donatelle, MD; Everett Rogers, DO; Lee Seiffer, MD; Ruben Porudominsky, MD; Francesco Vujeta, MD; Ayoola Olayiwola, MD; Claudio Tieda, MD; Mount Sinai Medical Center, Miami, Florida

**Session:** P-15. COVID-19 Diagnostics

**Background.** Cardiac adipose tissue in order to classify them as increased or decreased risk of cardiac dysfunction in COVID-19 patients. We conducted a retrospective cohort study assessing EAT Thickness and Density from 148 Participants were assigned to two groups based on epidemiological factors at the time of COVID-19 diagnosis and were associated with more worrisome COVID-19-related clinical outcomes.

**Conclusion.** This study reveals that non-cancer pts tended to have more radiologic findings on chest CT scan compared to cancer pts at the time of COVID-19 diagnosis and were associated with more worrisome COVID-19-related clinical outcomes.

**Disclosures.** All Authors: No reported disclosures

---

359. The Role of Procalcitonin in Antimicrobial Stewardship Among Cancer Patients Admitted with COVID-19

Hiba Dagher, MD; Anne-Marie Chaffari, MD; Ray Y. Hachem, MD; Yiang Jiang, MS; Alexandre Malek, MD; Natalie J Dailey Garnes, MD, MPH1; Jowan Borjan, PhD2; Victor Mulañitch, MD1; Issam I. Raad, MD1; UT MD Anderson Cancer Center, Houston, TX;1 The University of Texas MD Anderson Cancer Center, Houston, TX;2 MD Anderson Cancer Center, Houston, TX;3 University of Texas MD Anderson Cancer Center, Houston, TX

**Session:** P-15. COVID-19 Diagnostics

**Background.** Procalcitonin (PCT) has been used to guide antimicrobial therapy in bacterial infections. With the wide spread use of empiric use of antibiotics in cancer patients admitted with COVID-19 disease, we aimed to evaluate the role of PCT in decreasing the duration of empiric antimicrobial therapy among cancer patients admitted with COVID-19.

**Methods.** We conducted a retrospective study of cancer patients admitted to MD Anderson Cancer Center who had a PCT test done within 72 hours of admission following their COVID-19 diagnosis between March 1, 2020 and June 6, 2021. Patients were divided into 2 groups of PCT < 0.25 mg/mL and PCT ≥ 0.25 mg/mL. We assessed pertinent cultures including blood and respiratory, as well as antibacterial use and duration of empiric antimicrobial therapy.

**Results.** We identified 544 patients with a median age of 62 years (range: 14-93). There were 312 (57%) patients that had at least one culture obtained from a sterile or infected site within 7 days following admission. None of the patients who had PCT< 0.25 had a positive culture whereas 41/111 (37%) patients with PCT ≥ 0.25 had at least one positive culture [P=0.0001]. Among the 373 patients who had a PCT < 0.25, 129 (35%) patients received more than 72 hours of IV antibiotics compared to 87/171 (51%) among patients with PCT ≥ 0.25 [P=0.0003].

**Conclusion.** This study reveals that non-cancer pts tended to have more radiologic findings on chest CT scan compared to cancer pts at the time of COVID-19 diagnosis and were associated with more worrisome COVID-19-related clinical outcomes.

**Disclosures.** All Authors: No reported disclosures

---

*Abstracts*